We create innovative treatments for nervous system damage due to injury or disease.

NervGen Pharma

NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. Our lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury

NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.

For information regarding recruitment, the call center phone number is +1 (855) 559-6902. 

View our NervGen: the Origin Story Video

View our Corporate Presentation

Stay Connected

Subscribe to our mailing list to stay up to date

The Latest

News Release

September 30, 2024

NervGen announced that target enrollment of the chronic cohort in its Phase 1b/2a clinical trial for NVG-291 in individuals with spinal cord injury is approaching completion.  

News Release

August 22, 2024

NervGen reported its financial and operational results for the second quarter ended June 30, 2024.  

NEWS RELEASE

July 22, 2024

NervGen announced the appointment of Neil Klompas to its Board of Directors.